Global Contraceptives Market to 2029 - Featuring Reckitt Benckiser, Pfizer and Mayer Laboratories Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Contraceptives Market Analysis by Product (Topical, Oral Contraceptive Pills, Injectable Contraceptives), by Device (Male Condoms, Diaphragms, Female Condoms, Vaginal Rings, Sub Dermal Implants, Intra-Uterine Devices), and by Region - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The global contraceptives market size is estimated to be USD 23.52 billion in 2021 and is expected to witness a CAGR of 6.31% during the forecast period.

Companies Mentioned

• The Female Health Company (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Reckitt Benckiser Plc (U.K.)
• Pfizer Inc. (U.S.)
• Mayer Laboratories Inc. (U.S.)
• Cooper Surgical (U.S.)
• Church & Dwight Co. Inc. (U.S.)
• Actavis plc (U.S.)
• Merck & Co. (U.S.)
• Ansell Limited (Australia)

NGO and government initiatives to encourage use of contraceptive methods is a key driver for the growth of the global contraceptives market. Additionally, rising need for checking unwanted pregnancy and increase in awareness about contraceptives worldwide are some of the other drivers propelling the market growth. Nevertheless, health risks related with the usage of various contraceptive methods and rapid growth in aging population and rise in cases of infertility are expected to restrain the global market growth.

Key Topics Covered:

1. Research Methodology

2. Introduction: Contraceptives

3. Executive Summary

3.1.Global Market Scenario

3.2.Segment Market Scenario

3.3.Geographic Market Scenario

3.4.COVID-19 Impact

3.5.Competitive Landscape

4. Market Dynamics

5. Market Environment Analysis

5.1.Porter's 5 Forces Analysis

5.2.PESTEL Analysis

5.3.Value Chain Analysis

5.4.SWOT Analysis

5.5.Benchmark

6. COVID-19 Impact Analysis: Contraceptives Market

6.1.COVID-19: Overview

6.2.COVID-19 Impact on the Global Market

6.3.COVID-19 Impact on the Regional Markets

7. Market Analysis by Product

7.1.Topical contraceptives

7.1.1.Topical contraceptives Market Forecast, 2021-2029 (USD Million)

7.2.Oral contraceptive pills

7.2.1.Oral contraceptive pills Market Forecast, 2021-2029 (USD Million)

7.3.Injectable contraceptives

7.3.1.Injectable contraceptives Market Forecast, 2021-2029 (USD Million)

8. Market Analysis by Device

8.1.Contraceptive sponges

8.1.1.Contraceptive sponges Market Forecast, 2021-2029 (USD Million)

8.2.Male condoms

8.2.1.Male condoms Market Forecast, 2021-2029 (USD Million)

8.3.Diaphragms

8.3.1.Diaphragms Market Forecast, 2021-2029 (USD Million)

8.4.Female condoms

8.4.1.Female condoms Market Forecast, 2021-2029 (USD Million)

8.5.Vaginal rings

8.5.1.Vaginal rings Market Forecast, 2021-2029 (USD Million)

8.6.Subdermal implants

8.6.1.Subdermal implants Market Forecast, 2021-2029 (USD Million)

8.7.Intra-uterine devices

8.7.1.Intra-uterine devices Market Forecast, 2021-2029 (USD Million)

9. Regional Market Analysis

9.1.Regional Market Trends

9.2.Regional Market: Comparative Analysis

10. North America Contraceptives Market

11. Europe Contraceptives Market

12. Asia Pacific Contraceptives Market

13. Latin America Contraceptives Market

14. MEA Contraceptives Market

15. Competitor Analysis

15.1.Market Share Analysis, 2021 & 2029

15.2.Competitive Mapping

15.3.Key Players Market Place Analysis

15.4.Major Recent Developments

16. Company Profiles

16.1.The Female Health Company (U.K.)

16.1.1.Company Snapshot

16.1.2.Company Overview

16.1.3.Financials

16.1.4.Product Benchmarking

16.1.5.Recent Developments

16.2.Teva Pharmaceutical Industries Ltd. (Israel)

16.2.1.Company Snapshot

16.2.2.Company Overview

16.2.3.Financials

16.2.4.Product Benchmarking

16.2.5.Recent Developments

16.3.Pfizer, Inc. (U.S.)

16.3.1.Company Snapshot

16.3.2.Company Overview

16.3.3.Financials

16.3.4.Product Benchmarking

16.3.5.Recent Developments

16.4.Mayer Laboratories, Inc. (U.S.)

16.4.1.Company Snapshot

16.4.2.Company Overview

16.4.3.Financials

16.4.4.Product Benchmarking

16.4.5.Recent Developments

16.5.Cooper Surgical (U.S.)

16.5.1.Company Snapshot

16.5.2.Company Overview

16.5.3.Financials

16.5.4.Product Benchmarking

16.5.5.Recent Developments

16.6.Church & Dwight Co. Inc. (U.S.)

16.6.1.Company Snapshot

16.6.2.Company Overview

16.6.3.Financials

16.6.4.Product Benchmarking

16.6.5.Recent Developments

16.7.Actavis plc (U.S.)

16.7.1.Company Snapshot

16.7.2.Company Overview

16.7.3.Financials

16.7.4.Product Benchmarking

16.7.5.Recent Developments

16.8.Merck & Co. (U.S.)

16.8.1.Company Snapshot

16.8.2.Company Overview

16.8.3.Financials

16.8.4.Product Benchmarking

16.8.5.Recent Developments

16.9.Ansell Limited (Australia)

16.9.1.Company Snapshot

16.9.2.Company Overview

16.9.3.Financials

16.9.4.Product Benchmarking

16.9.5.Recent Developments

16.10.Dilon Technologies, Inc. (US)

16.10.1.Company Snapshot

16.10.2.Company Overview

16.10.3.Financials

16.10.4.Product Benchmarking

16.10.5.Recent Developments

16.11.Planmed Oy (Finland)

16.11.1.Company Snapshot

16.11.2.Company Overview

16.11.3.Financials

16.11.4.Product Benchmarking

16.11.5.Recent Developments

16.12.Delphinus Medical Technologies, Inc. (US)

16.12.1.Company Snapshot

16.12.2.Company Overview

16.12.3.Financials

16.12.4.Product Benchmarking

16.12.5.Recent Developments

17.Conclusion & Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/eioyj9

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900